-transparent.png){kind=logo}
A model describing the development of cardiotoxicity as a function of cumulative dose of a drug and other covariates is presented. Methods are given for testing and illustrating a cumulative dose effect. Also, equations for estimation of the probability of developing cardiotoxicity in the presence or absence of competing risks are given. The methods are illustrated for mitoxantrone by means of data obtained from Southwest Oncology Group studies.
Related Publications
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
November 1985,
Cancer treatment reports,
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
February 1985,
Cancer treatment reports,
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
September 1982,
Cancer treatment reports,
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
February 1990,
Investigational new drugs,
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
January 1983,
Investigational new drugs,
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
June 1984,
Cancer treatment reports,
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
January 1994,
Investigational new drugs,
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
January 1992,
European journal of cancer (Oxford, England : 1990),
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
January 1979,
Cancer treatment reports,
F J Mather, and
R M Simon, and
G M Clark, and
D D Von Hoff
June 1987,
Gynecologic oncology,
